Login to Your Account

Other News To Note

Wednesday, January 30, 2013
• Addex Therapeutics SA, of Geneva, reported that its product candidate dipraglurant showed robust and dose-dependent reduction in severity of dystonia-like attacks in a mouse model.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription